Virax Biolabs Reports Positive Early Clinical Data for ViraxImmune™ in Long COVID and Related Post-Acute Infection Syndromes

Virax Biolabs Group Limited announced positive early pilot data for ViraxImmune™, a blood-based diagnostic test for Long COVID and related post-acute infection syndromes. The test demonstrated 88% specificity and 92% positive predictive value in separating PAIS patients from healthy controls across 120+ subjects. The company plans a larger clinical validation study with 300 additional participants, with analysis expected in Q4 2026 and results in Q1 2027, targeting a U.S. Laboratory Developed Test market entry.